pletely prevents GVHD, 2 and suppression of recipient T cells by administration of anti-lymphocyte antibodies before graft infusion reduces the risk of graft rejection.
6
Cytokine-induced excessive production of NO, however, presented, it can be tentatively postulated that nitric oxide is a common proximate regulator of the immune has been implicated in the pathogenesis of inflammatory conditions such as ulcerative colitis 7 and rheumatoid response in host-versus-graft and graft-versus-host reactions.
arthritis. 8 Recent animal studies have also documented enhanced NO production in both host-versus-graft and Keywords: nitric oxide; host-versus-graft; graft-versushost graft-versus-host reactions 9,10 but it is unclear what its exact role in the pathogenesis of these conditions is, since in one of these studies 10 inhibition of NO production paradoxically resulted in reduced survival of animals due to impairment Cell damage in the major non-infective complications of of alloengraftment. allogeneic transplantation is caused by a complex interacTo establish whether cytokine-induced enhancement of tion between the toxicity of the conditioning regimen, and NO production occurs in human allograft recipients with donor and host immune responses. Graft-versus-host dis-GVH/HVG reactions, we have compared cytokine and ease (GVHD) and graft rejection are two such complinitrate levels in patients undergoing allogeneic and autologcations which are thought to be primarily immuneous transplants, patients with post-chemotherapy febrile mediated, and some aspects of the immune perturbation neutropenia and normal blood donors. accompanying them have been recently defined.
1 T lymphocytes seem to be essential for the initiation of both reactions, since removal of T cells from the graft almost com- 
Patients and methods

Patients (
Statistical analysis
Normal Blood donors 27 controls Peak levels of IL-1␤, TNF-␣, sIL2R and nitrate in the transplant and control groups were compared using the MannWhitney two-tailed test. patients) transplantation for a variety of malignant and nonmalignant disorders were recruited to the study. A majority Results of autologous transplant patients were conditioned with BEAM combination chemotherapy whereas cyclophosphamide plus fractionated TBI was used to condition a Four allogeneic transplant recipients suffered a major transplant-related complication (Table 2) : an 8-month-old child majority of allograft recipients. Graft-versus-host disease prophylaxis consisted of cyclosporine alone (five patients), died of veno-occlusive disease (VOD) 2 weeks posttransplant; a 35-year-old male developed fatal fulminant or with short-course methotrexate (three patients), in all except one patient who received a T cell-depleted, two antinon-infective cholestatic hepatitis with non-specific liver histology at autopsy; one patient had steroid-responsive gen mismatched related graft.
grade IV isolated liver GVHD; and a 12-year-old girl with severe aplastic anaemia rejected her graft at day 14 postControls (Table 1) transplant and reconstituted autologous haemopoiesis. Peak serum nitrate, IL-1␤ and TNF-␣, but not sIL2R, Patients (age 1-65 years) with post-chemotherapy febrile neutropenia served as patient controls and normal blood levels were significantly higher in these patients compared to allograft recipients with an uncomplicated postdonors as normal controls.
transplant course, autograft recipients (including one with fatal endothelial leak syndrome), patient controls and norMethods mal controls ( Figure 1 and Table 3 ). There was an interesting difference, however, in the dynamics of nitrate and Venous blood samples were collected from the transplant group pre-transplant, during conditioning, and at regular cytokine increases between the patients with graft-versus- Allogeneic without complications 34 ± 12 42 ± 7 6 ± 4 3340 ± 1195 P = 0.02 P = 0.02 P = 0.12* P = 0.53 Autologous 50 ± 14 85 ± 9 8 ± 5 3192 ± 610 P = 0.01 P = 0.01 P = 0.04
Patient controls 40 ± 16 29 ± 8 2 ± 1 2363 ± 526 P = 0.006 P = 0.007 P = 0.02 P = 0.07 Normal controls 12 ± 2 2 6 ± 3 5 ± 5 399 ± 34 P = 0.001 P = 0.001 P = 0.02 P = 0.001 P values were calculated using Mann-Whitney two-tailed test to compare mean peak levels in allogeneic transplant patients with complications with other groups. *P = 0.01 if patient with fulminant hepatitis excluded.
host/host-versus-graft reactions (Figure 2 , cases 1 and 2), and those with veno-occlusive disease and cholestatic hepatitis ( Figure 2 , cases 3 and 4). In the former, peak levels preceded the complication by just 2-3 days, whereas in the latter the increase in levels occurred during conditioning therapy, well before the onset of signs and symptoms of the complication.
Discussion
Serum cytokine and nitric oxide levels are elevated in patients with severe non-infective complications after allogeneic transplants, more so than in autograft recipients with transplant complications or immuno-compromised infected patients. But whereas the increase in levels accompanied pre-transplant conditioning therapy in veno-occlusive disease and cholestatic hepatitis, in GVH/HVG reactions the increase occurred during the period of early graft recovery and a few days before the clinical manifestations, indicating that the initiating factors for these two groups of complications are different; the former most likely to be due to a direct effect of chemoradiotherapy and the latter by activation of immune mechanisms involving T cell recognition of donor/recipient HLA mismatches. Our tentative observations in human transplant recipients support previous animal studies indicating a role for NO in both graft-versus-host and host-versus-graft reactions. 9,10 A single previous study has also documented increased NO production in human allograft recipients with acute GVHD.
12 Human solid organ rejection has been reported to be associated with an increase in serum nitrate and nitrite levels 13 but our observation of a similar increase preceding human marrow graft rejection has not been reported before. In common with the observation reported by these earlier studies we have also found that NO production peaks 2-3 days before clinical manifestations of GVH/HVG. Therefore, serial measurement of serum nitrate/nitrite levels posttransplant, as recommended by previous investigators 9, 10, 13 may allow early diagnosis and treatment to abort, or ameliorate the severity of, the clinical manifestations of GVH/HVG reactions. However, as we have observed, nitrate and nitrite levels are also raised in other serious posttransplant complications including, as others have documented, 13 in severe infections. Since the peak levels occur during conditioning in the former and the magnitude of increase is less in the latter, 13 the timing and threshold level of increases would need to be defined before their specificity for GVH/HVG reactions is sufficient to make monitoring of serum nitrate and nitrite levels post-transplant clinically useful. We are soon to embark on a study to address these issues.
What is the exact role of nitric oxide in the pathophysiology of these reactions? Nitric oxide released by tissue does not exacerbate it, 10 NO has been implicated as a pro-
